MAP2K7 and leukemia: This implicates an increased transcriptional activity of the MEK/ERK signaling pathway including negative feedback regulators in leukemia with signaling mutations, in particular those with FLT3N676K and NRASG12D, and that the mutant cells are insensitive to negative feedback control.